期刊文献+

Human Papillomavirus 16E6 Oncogene Mutation in Cervical Cancer 被引量:1

Human Papillomavirus 16E6 Oncogene Mutation in Cervical Cancer
下载PDF
导出
摘要 Objective: Cervical cancer (CC) is the second most common type of cancer in women worldwide, after breast cancer. High-risk human papillomaviruses (HR-HPVs) are considered to be the major causes of cervical cancer. HPV16 is the most common type of HR-HPVs and HPV16 E6 gene is one of the major oncogenes. Specific mutations are considered as dangerous factors causing CC. This study was designed to find mutations of HPV16 E6 and the relationship between the mutations and the happening of CC. Methods: The tissue DNA was extracted from 15 biopsies of CC. Part of HPV16 E6 gene (nucleotide 201-523) was amplified by polymerase chain reaction (PCR) from the CC tissue DNA. The PCR fragments were sequenced and analyzed. Results: The result of PCR showed that the positive rate of HPV16 E6 was 93.33% (14/13). After sequencing ana analyzing, in the 13 out of 14 PCR fragments, 4 maintained prototype (30.77%), 8 had a same 350G mutation (61.54%), and 1 had a 249G mutation (7.69%). Conclusion: This study suggest that there is a high infection rate of HPV in cervical cancer and most of the HPV16 E6 gene has mutations. Those mutations may have an association with the development of cervical cancer. Objective: Cervical cancer (CC) is the second most common type of cancer in women worldwide, after breast cancer. High-risk human papillomaviruses (HR-HPVs) are considered to be the major causes of cervical cancer. HPV16 is the most common type of HR-HPVs and HPV16 E6 gene is one of the major oncogenes. Specific mutations are considered as dangerous factors causing CC. This study was designed to find mutations of HPV16 E6 and the relationship between the mutations and the happening of CC. Methods: The tissue DNA was extracted from 15 biopsies of CC. Part of HPV16 E6 gene (nucleotide 201-523) was amplified by polymerase chain reaction (PCR) from the CC tissue DNA. The PCR fragments were sequenced and analyzed. Results: The result of PCR showed that the positive rate of HPV16 E6 was 93.33% (14/13). After sequencing ana analyzing, in the 13 out of 14 PCR fragments, 4 maintained prototype (30.77%), 8 had a same 350G mutation (61.54%), and 1 had a 249G mutation (7.69%). Conclusion: This study suggest that there is a high infection rate of HPV in cervical cancer and most of the HPV16 E6 gene has mutations. Those mutations may have an association with the development of cervical cancer.
出处 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2009年第2期97-101,共5页 中国癌症研究(英文版)
基金 supported by a grant from the 11th Five-year Plan Medical Science Fundation of PLA (No06MA084)
关键词 Cervical cancer Human papUlomavirus E6 gene MUTATION Cervical cancer Human papUlomavirus E6 gene Mutation
  • 相关文献

参考文献1

二级参考文献18

  • 1李庭芳,古力娜.库尔班,古丽沙热,贺国丽,王涛,海日古丽,王振华.新疆伽师县夏普桃勒乡妇女子宫颈癌防治研究[J].新疆医学院学报,1996,19(3):199-203. 被引量:64
  • 2Matsumoto K, Yoshikawa H, Nakagawa S, et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population [J]. Cancer Lett,2000,156:159- 165.
  • 3Londesborough P, Ho L, Terry G, et al. Human papillomavirus genotype as a predictor of persistence and development of high grade lesions in women with minor cervical abnormalities [J]. Int J Cancer, 1996, 69:364- 368.
  • 4Zehbe I, Wilander E, Delius H, et al. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype [J]. Cancer Res, 1998, 58:829- 833.
  • 5Zehbe I, Voglino G, Wilander E, et al. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development [J]. Cancer Res, 2001, 61:608- 611.
  • 6Zehbe I, Voglino G, Delius H, et al. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms [J]. Lancet, 1998, 352:1441- 1442.
  • 7Zehbe I, Tachezy R, Mytilineos J. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes [J]. Int J Cancer, 2001, 94:711- 716.
  • 8Matsumoto K, Yasugi, Nakagawa S. Human papillomavirus 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer [J]. Int J Cancer, 2003, 106:919- 922.
  • 9Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta analysis [J]. Br J Cancer, 2003, 88:63- 73.
  • 10Hwang TS, Jeong JK, Park M, et al. Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray [J]. Gynecol Oncol, 2003,90:51- 56.

共引文献16

同被引文献34

  • 1乌兰娜,吴瑞芳,周艳秋,刘志红,张礼婕,黄秀浓,杜辉.人乳头瘤病毒基因亚型与宫颈病变的关系[J].中国妇产科临床杂志,2005,6(5):346-350. 被引量:102
  • 2zur Hausen H.Papillomaviruses and cancer:from basic studies to clinical application[J].Nat Rev Cancer,2002,2(5):342-350.
  • 3IARC monograph on the evaluation of carcinogenic risks to humans.Human papillomaviruses:International Agency for Research on Cancer,2005:105-108.
  • 4Bosch FX,Lorincz A,Munoz N,et al.The causal relation between human papillomavirus and cervical cancer[J].J Clin Pathol,2002,55 (4):244-265.
  • 5Lechner MS,Laimins LA.Inhibition of p53 DNA binding by human papilloma virus E6 protein[J].J Virol,1994,68(7):4262-4273.
  • 6Qiu AD,Wu EQ,Yu XH,et al.HPV prevalence,E6 sequence variation and physical state of HPV16 isolates from patients with cervical cance in Sichuan,China[J].Gynecol Oncol,2007,104(1):77-85.
  • 7Radhakrishna Pillai M,Sreevidya S,Pollock BH,et al.Human papillomavirus type 16 E6 and E7 gene variations in Indian cervical cancer[J].Gynecol Oncol,2002,87(3):268-273.
  • 8Vaeteewoottacharn K,Jearanaikoon P,Ponglikitmongkol M.Co-mutation of human papillomavirus type 16 E6 and E7 genes in Thaisquamous cervical carcinomas[J].Anticancer Res,2003,23(2c):l927-l931.
  • 9Dell'Atti D,Zavaglia M,Tombelli S.Development of combined DNA-based piezoelectric biosensors for the simultaneous detection and genotyping of high risk human papilloma virus strains[J].Clinica Chimica Acta,2007,383(1-2):140-146.
  • 10Rozendaal L,Westerga J,van der Linden JC,et al.PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN Ⅲ in women with normal cytology and borderline changes[J].J Clin Pathol,2000,53(8):606-611.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部